(Q37701568)

22 August 2017

1 reference

title

The potential of 3',5'-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant (English)

1 reference

22 August 2017

1 reference

1 reference

Wangxue Chen

1

1 reference

22 August 2017

Rhonda Kuolee

series ordinal

2

1 reference

22 August 2017

Hongbin Yan

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

28

1 reference

22 August 2017

3080-3085

1 reference

22 August 2017

18

1 reference

The global eradication of poliomyelitis: progress and problems

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Mucosal vaccines: the promise and the challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Immunomodulators and delivery systems for vaccination by mucosal routes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Preclinical and clinical safety studies on DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Vaccine development strategies for improving immunization: the role of modern immunology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Mechanism of action of licensed vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Regulation of cellulose synthesis in Acetobacter xylinum by cyclic diguanylic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Bacterial signal transduction network in a genomic perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Cyclic diguanylate is a ubiquitous signaling molecule in bacteria: insights into biochemistry of the GGDEF protein domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Cell cycle-dependent dynamic localization of a bacterial response regulator with a novel di-guanylate cyclase output domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Cyclic di-GMP as a second messenger

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Structural and mechanistic determinants of c-di-GMP signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Cyclic di-guanosine-monophosphate comes of age: a novel secondary messenger involved in modulating cell surface structures in bacteria?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Cyclic diguanylate (c-di-GMP) regulates Vibrio cholerae biofilm formation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

C-di-GMP: the dawning of a novel bacterial signalling system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

GGDEF and EAL domains inversely regulate cyclic di-GMP levels and transition from sessility to motility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

3',5'-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Bacterial c-di-GMP is an immunostimulatory molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Synthesis and immunostimulatory properties of the phosphorothioate analogues of cdiGMP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

3',5'-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

3',5'-cyclic diguanylic acid reduces the virulence of biofilm-forming Staphylococcus aureus strains in a mouse model of mastitis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

c-di-GMP (3'-5'-cyclic diguanylic acid) inhibits Staphylococcus aureus cell-cell interactions and biofilm formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Mucosal vaccination against encapsulated respiratory bacteria--new potentials for conjugate vaccines?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Recent advances in vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Improving M cell mediated transport across mucosal barriers: do certain bacteria hold the keys?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Novel generations of influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Vaccination strategies for mucosal immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Liposomes and ISCOMS as vaccine formulations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Great times for small molecules: c-di-AMP, a second messenger candidate in Bacteria and Archaea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

Structural biochemistry of a bacterial checkpoint protein reveals diadenylate cyclase activity regulated by DNA recombination intermediates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

The member of the cyclic di-nucleotide family bis-(3', 5')-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.081

10.1016/J.VACCINE.2010.02.081

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference